Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
TARS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.08 - $57.28
Previous CloseN/A
Volume127.14K
Average Volume (3M)635.77K
Market Cap
$2.08B
Enterprise Value$1.02B
Total Cash (Recent Filing)$193.71M
Total Debt (Recent Filing)$30.52M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
May 13, 2025EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding41,607,513
10 Day Avg. Volume619,085
30 Day Avg. Volume635,768
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.79
Price to Cash Flow (P/CF)-55.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.98
Enterprise Value/Ebitda-9.55
Forecast
1Y Price Target
$67.63Price Target Upside29.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Tarsus Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Market PenetrationThe increase in Xdemvy prescriptions and surpassing the initial target prescriber base indicates robust demand and market penetration.
Sales PerformanceTarsus Pharmaceuticals reported strong earnings with significant growth, beating consensus estimates for the fifth consecutive quarter.
Stock ValuationThe stock is considered undervalued based on U.S. XDEMVY potential and future opportunities from ex-US revenue and product pipeline.
Bears Say
Development RisksConcerns about the risk-profile of the TP-05 development for Lyme disease prevention are affecting investor sentiment.
Investor ConcernsInvestor concerns include cautious 1Q XDEMVY bottle volume guidance and increased spending on marketing and R&D, which have contributed to a stock decline.
Spending UncertaintyHigher R&D spending for the development of TP-04 and TP-05 projects involves uncertainties and potential risks.
---
Ownership Overview
3.20% Insiders
17.85% Mutual Funds
44.55% Other Institutional Investors
21.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $20.08 and its highest was $57.28 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Tarsus Pharmaceuticals’s market cap is $2.08B.
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 47 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Feb 25, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.743 by $0.143.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -0.81.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 41,607,513 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.743. Following the earnings report the stock price went down -9.332%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Currently, no hedge funds are holding shares in TARS
---
Tarsus Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.63 (29.16% Upside)
$67.63 (29.16% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 658.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 14.4%
Last 30 Days ▼ 14.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.78%
12-Months-Change
Fundamentals
Return on Equity
-54.83%
Trailing 12-Months
Asset Growth
41.74%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
---
TARS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a year of strong financial performance and strategic advancements in Tarsus' pipeline, particularly with the success of XDEMVY and preparations for future product launches. However, challenges such as increased operational costs and anticipated headwinds in early 2025 were noted.Read More>---
TARS Stock 12 Month Forecast
Average Price Target
$67.63
▲(29.16% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Rocket Pharmaceuticals
―
Verona Pharma
―
scPharmaceuticals
―
Best Analysts Covering TARS
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+55.63%
reiterated a buy rating 21 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +55.63% per trade.
---